Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Experimental Therapeutics

Lysostaphin Treatment of Experimental Aortic Valve Endocarditis Caused by a Staphylococcus aureus Isolate with Reduced Susceptibility to Vancomycin

Roberto L. Patron, Michael W. Climo, Beth P. Goldstein, Gordon L. Archer
Roberto L. Patron
Department of Internal Medicine and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael W. Climo
Department of Internal Medicine and
Hunter Holmes McGuire Veterans Affairs Medical Center, Richmond, Virginia, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Beth P. Goldstein
AMBI, Inc., Purchase, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gordon L. Archer
Department of Internal Medicine and
Microbiology/Immunology, Medical College of Virginia Campus of Virginia Commonwealth University, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.43.7.1754
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

The rabbit model of endocarditis was used to test the effectiveness of vancomycin and two different lysostaphin dosing regimens for the treatment of infections caused by a Staphylococcus aureusstrain with reduced susceptibility to vancomycin (glycopeptide-intermediate susceptible S. aureus [GISA]). Vancomycin was ineffective, with no evidence of sterilization of aortic valve vegetations. However, rates of sterilization of aortic valve vegetations were significantly better for animals treated with either a single dose of lysostaphin (43%) or lysostaphin given twice daily for 3 days (83%) than for animals treated with vancomycin. Rabbits given a single dose of lysostaphin followed by a 3-day drug-free period had mean reductions in aortic valve vegetation bacterial counts of 7.27 and 6.63 log10 CFU/g compared with those for untreated control rabbits and the vancomycin-treated group, respectively. We conclude that lysostaphin is an effective alternative for the treatment of experimental aortic valve endocarditis caused by a clinical VISA strain.

Lysostaphin is a 27-kDa peptidase that is produced by Staphylococcus simulans and that specifically cleaves the pentaglycine cross-links unique to the cell wall of Staphylococcus aureus (11, 16). The antimicrobial properties of lysostaphin were studied in the 1960s and 1970s, but it was never developed as a therapeutic agent (3-6, 12-14). Recently, we reexamined the therapeutic potential of lysostaphin in the treatment of staphylococcal infection using the rabbit model of experimental aortic valve endocarditis (2). In the treatment of experimental endocarditis caused by methicillin-resistantS. aureus, lysostaphin demonstrated excellent bactericidal activity, with a significant reduction in mean aortic valve vegetation counts of 8.5 log10 CFU/g compared with that for the control group (2). With the recent emergence of S. aureus strains with reduced susceptibility to vancomycin (glycopeptide-intermediate susceptible S. aureus[GISA]) (7, 10, 15), we decided to study the in vitro and in vivo activities of lysostaphin against a clinical isolate of VISA.

Lysostaphin MICs were determined by the broth microdilution method in cation-adjusted Mueller-Hinton broth (Becton Dickinson, Cockeysville, Md.) according to the standards of the National Committee for Clinical Laboratory Standards (8), with a final inoculum of 105 CFU/ml. Bovine serum albumin (0.1%; Sigma) was added to prevent the adsorption of lysostaphin to polystyrene microtiter wells.

The rabbit model of aortic valve endocarditis, which has been described previously (1, 2, 9), was used to evaluate the antibiotic treatment regimens. A total of 33 female White New Zealand rabbits weighing 2 to 3 kg were injected intravenously through the marginal ear vein with 1 ml of an overnight culture containing 107 CFU of VISA HIP5827 per ml. HIP5827 is a clinical isolate recovered from a patient in Michigan in 1996. The vancomycin MIC for this isolate is 8 μg/ml and was kindly provided by Fred Tenover, Centers for Disease Control and Prevention (15).

Rabbits were assigned to one of four different treatment groups: (i) the control group, which received no treatment, (ii) a group that received lysostaphin (30 mg/kg of body weight twice a day [b.i.d.]) intravenously for 3 days, (iii) a group that received a single intravenous dose of lysostaphin (100 mg/kg) followed by a 3-day drug-free period, or (iv) a group that received the standard intravenous vancomycin dosage (30 mg/kg b.i.d.) for 3 days. The vancomycin dosage of 30 mg/kg b.i.d. was chosen because it has been shown to achieve peak levels similar to those observed in humans (1). Recombinant lysostaphin was supplied by AMBI, Inc., Purchase, N.Y., and was stored at 4°C. Fresh solutions were prepared daily in 0.05 M Tris HCl–0.145 M NaCl. Vancomycin was obtained from Abbott Laboratories, Chicago, Ill.

Four days after infection and at least 18 h after administration of the last dose of antibiotics to the 3-day treatment groups, the rabbits were killed and their hearts and kidneys were aseptically removed. Aortic valve vegetations and kidney abscesses or infarcts were removed, weighed, homogenized in saline, and serially diluted. Dilutions were plated on Mueller-Hinton agar, and the plates were incubated at 37°C for 48 h. Titers of bacteria were expressed as log10 CFU per gram of tissue. Sterile aortic vegetation cultures contained ≤2 log10 CFU/g, and sterile kidneys contained ≤1 log10 CFU/g (the limit of detection). The mean numbers of bacteria per gram of vegetation and kidney tissue in all treatment groups were compared by analysis of variance. The Student-Newman-Keuls test was used to adjust for multiple comparisons. For analysis of the rate of sterilization, we used Fisher’s exact test (two-tailed) with the permutation-style adjustment for multiple comparisons. A P value of <0.05 was considered statistically significant for all tests.

The MICs of antibacterial agents for HIP5827 were as follows: oxacillin, >500 μg/ml; vancomycin, 8 μg/ml; and lysostaphin, 0.0039 μg/ml. The results obtained from the 3-day antibiotic treatment regimen for experimental endocarditis caused by HIP5827 are presented in Table 1. Control rabbits had a mean ± standard deviation aortic valve vegetation bacterial count of 10.3 ± 0.51 log10 CFU/g, which is comparable to those reported previously from trials of endocarditis caused by methicillin-resistant S. aureus (1). As expected, vancomycin given twice daily was ineffective in treating experimental aortic valve endocarditis, with a mean aortic valve vegetation bacterial count reduction of 0.64 log10 CFU/g compared with that for the untreated control group.

View this table:
  • View inline
  • View popup
Table 1.

Outcome of 3-day treatment of experimental GISA aortic valve endocarditis with lysostaphin

Lysostaphin treatment by both regimens was very effective. The group dosed b.i.d. had mean aortic valve vegetation bacterial count reductions of 8.27 log10 CFU/g (P < 0.05) and 7.63 log10 CFU/g (P < 0.05) compared with those for the untreated control and vancomycin groups, respectively. The group that received a single dose of lysostaphin had similar results, with reductions in mean aortic valve vegetation bacterial counts of 7.27 log10 CFU/g (P < 0.05) and 6.63 log10 CFU/g (P < 0.05) compared with those for the untreated control and vancomycin groups, respectively. There was no statistical difference in the counts between the two lysostaphin treatment groups. Colonies of bacteria isolated from vegetation material from rabbits treated with lysostaphin underwent broth microdilution susceptibility testing, and the lysostaphin MIC for these strains was not increased compared to that for the untreated parent strain.

Rates of sterilization of aortic valve vegetations were also better for the two lysostaphin treatment groups than for either the vancomycin group or the untreated control group. Rates of sterilization of aortic valve vegetations were 83% for the group that received lysostaphin b.i.d. (P = 0.02 versus the vancomycin group) and 43% for the group that received a single dose of lysostaphin (P = 0.06 versus the vancomycin group). None of the rabbits treated with vancomycin had sterile aortic valve vegetations. The difference in rates of sterilization between the two lysostaphin treatment groups was not statistically significant (P = 0.2).

Table 1 also shows the results of kidney tissue cultures for the different treatment groups. Both lysostaphin dosing regimens resulted in statistically significant reductions in bacterial counts in kidney tissue compared with those for the untreated control group (P < 0.05). Rates of sterilization of kidney tissue bacterial cultures were 66.6% for the group that received lysostaphin b.i.d. (P = 0.01 versus the vancomycin group) and 100% for the group that received a single dose of lysostaphin (P = 0.0001 versus vancomycin). The difference between the two lysostaphin treatment groups was not statistically significant (P = 0.1).

Treatment of the rabbit model of experimental aortic valve endocarditis caused by GISA HIP5827 was unsuccessful following vancomycin monotherapy. In contrast, two different dosing regimens of lysostaphin produced significant numbers of sterile aortic valve vegetations and a significant reduction in bacterial counts in both aortic valve vegetations and kidney tissues. More importantly, administration of a single intravenous dose of lysostaphin, followed by a 3-day antibiotic-free period, sterilized 43% of aortic valve vegetations. Our results suggest that intravenous lysostaphin is an effective alternative for the treatment of aortic valve endocarditis caused by a clinical GISA strain. These results support further studies of the clinical use of lysostaphin for the treatment of severe human infections caused by S. aureus strains with reduced susceptibility to vancomycin.

ACKNOWLEDGMENTS

This work was supported by NIH STTR grant R-41HL60334.

We thank Geri Hale Cooper and Elizabeth Hanners for technical assistance.

FOOTNOTES

    • Received 4 December 1998.
    • Returned for modification 4 February 1999.
    • Accepted 6 April 1999.
  • Copyright © 1999 American Society for Microbiology

REFERENCES

  1. 1.↵
    1. Climo M. W.,
    2. Markowitz S. M.,
    3. Williams D. S.,
    4. Hale-Cooper C. G.,
    5. Archer G. L.
    Comparison of in-vitro and in-vivo efficacy of FK037, vancomycin, imipenem and nafcillin against staphylococcal species. J. Antimicrob. Chemother. 40 1997 59 66
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    1. Climo M. W.,
    2. Patron R. L.,
    3. Goldstein B. P.,
    4. Archer G. L.
    Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis. Antimicrob. Agents Chemother. 42 1998 1355 1360
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Dixon R. E.,
    2. Goodman J. S.,
    3. Koenig M. G.
    Lysostaphin: an enzymatic approach to staphylococcal disease. III. Combined lysostaphin-methicillin therapy of established staphylococcal abscesses in mice. Yale J. Biol Med. 41 1968 62 68
    OpenUrlPubMedWeb of Science
  4. 4.↵
    1. Goldberg L. M.,
    2. DeFranco J. M.,
    3. Watanakunakorn C.,
    4. Hamburger M.
    Studies in experimental staphylococcal endocarditis in dogs. VI. Treatment with lysostaphin 1967 45 53 Antimicrob. Agents Chemother. 1966.
  5. 5.↵
    1. Harrison E. F.,
    2. Cropp C. B.
    Therapeutic activity of lysostaphin in experimental staphylococcal infections. Can. J. Microbiol. 13 1967 93 97
    OpenUrl
  6. 6.↵
    1. Harrison E. F.,
    2. Zygmunt W. A.
    Lysostaphin in experimental renal infections. J. Bacteriol. 93 1967 520 524
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Hiramatsu K.,
    2. Hanaki H.,
    3. Ino T.,
    4. Yabuta K.,
    5. Oguru T.,
    6. Tenover F. C.
    Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40 1997 135 146
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    National Committee for Clinical Laboratory Standards Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically. Approved standard M7-A4 4th ed. 1997 National Committee for Clinical Laboratory Standards Wayne, Pa
  9. 9.↵
    1. Perlman B. B.,
    2. Freedman L. R.
    Experimental endocarditis. II. Staphylococcal infection of the aortic valve following placement of a polyethylene catheter in the left side of the heart. Yale J. Biol. Med. 44 1971 206 213
    OpenUrlPubMedWeb of Science
  10. 10.↵
    1. Ploy M. C.,
    2. Grelaud C.,
    3. Martin C.,
    4. de Lumley L.,
    5. Denis F.
    First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet 351 1998 1212
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    1. Schaffner W.,
    2. Melly M. A.,
    3. Hash J. H.,
    4. Koenig M. G.
    Lysostaphin: an enzymatic approach to staphylococcal disease. I. In vitro studies. Yale J. Biol. Med. 39 1967 215 229
    OpenUrlPubMedWeb of Science
  12. 12.↵
    1. Schaffner W.,
    2. Melly M. A.,
    3. Koenig M. G.
    Lysostaphin: an enzymatic approach to staphylococcal disease. II. In vivo studies. Yale J. Biol. Med. 39 1967 230 244
    OpenUrlPubMedWeb of Science
  13. 13.↵
    1. Schuhardt V. T.,
    2. Schindler C. A.
    Lysostaphin therapy in mice infected with Staphylococcus aureus. J. Bacteriol. 88 1964 815 816
    OpenUrlFREE Full Text
  14. 14.↵
    1. Stark F. R.,
    2. Thornsvard C.,
    3. Flannery E. P.,
    4. Artenstein M. S.
    Systemic lysostaphin in man. Apparent antimicrobial activity in a neutropenic patient. N. Engl. J. Med. 291 1974 239 240
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.↵
    1. Tenover F. C.,
    2. Lancaster M. V.,
    3. Hill B. C.,
    4. Steward C. D.,
    5. Stocker S. A.,
    6. Hancock G. A.,
    7. O’Hara C. M.,
    8. Clark N. C.,
    9. Hiramatsu K.
    Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J. Clin. Microbiol. 36 1998 1020 1027
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Zygmunt W.,
    2. Tavormina P. A.
    Lysostaphin: model for a specific enzymatic approach to infectious disease. Prog. Drug. Res. 16 1972 309 333
    OpenUrlPubMed
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
Lysostaphin Treatment of Experimental Aortic Valve Endocarditis Caused by a Staphylococcus aureus Isolate with Reduced Susceptibility to Vancomycin
Roberto L. Patron, Michael W. Climo, Beth P. Goldstein, Gordon L. Archer
Antimicrobial Agents and Chemotherapy Jul 1999, 43 (7) 1754-1755; DOI: 10.1128/AAC.43.7.1754

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Lysostaphin Treatment of Experimental Aortic Valve Endocarditis Caused by a Staphylococcus aureus Isolate with Reduced Susceptibility to Vancomycin
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Lysostaphin Treatment of Experimental Aortic Valve Endocarditis Caused by a Staphylococcus aureus Isolate with Reduced Susceptibility to Vancomycin
Roberto L. Patron, Michael W. Climo, Beth P. Goldstein, Gordon L. Archer
Antimicrobial Agents and Chemotherapy Jul 1999, 43 (7) 1754-1755; DOI: 10.1128/AAC.43.7.1754
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Anti-Bacterial Agents
Aortic Valve
Endocarditis, Bacterial
Heart Valve Diseases
Lysostaphin
staphylococcal infections
vancomycin

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596